SERDs and Novel ET in ER+/HER2- Breast Cancer
Oral SERDs and Novel Endocrine Therapies: Reshaping the Treatment Landscape for ER+/HER2- Breast Cancer

Released: December 01, 2023

Activity

Progress
1
Course Completed